Regeneron (1REGN) AI Stock Analysis
Regeneron
(Milan:1REGN)
No summary available
Regeneron (1REGN) vs. iShares MSCI Italy ETF (EWI)
- Market Cap
- EUR 98.95B
- Dividend Yield
- 0.37%
- Average Volume (3M)
- 12
- Price to Earnings (P/E)
- 20.5
- Beta (1Y)
- 0.44
- Revenue Growth
- 12.96%
- EPS Growth
- 4.10%
- Country
- Italy
- Employees
- 15,410
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Regeneron Business Overview & Revenue Model
Company Description
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA,...
Regeneron Earnings Call Summary
The call was strongly positive, supported by 36% revenue growth, 70% earnings-per-share growth, record sales for Dupixent, EYLEA HD, and Libtayo, strong cash generation, an expanded Sanofi alliance, and substantial progress across a broad clinical pipeline. The principal challenges were declining EYLEA sales and demand, biosimilar and pricing pressure, modest lynozyfic growth in its current setting, a higher expected tax rate, and no anticipated Inmazeb revenue in the fourth quarter of 2026. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter, EYLEA HD sequential growth is expected to be approximately 10%, partially offset by ongoing pricing pressure, while EYLEA sequential demand is expected to decline in the low- to mid-teens; full year EYLEA HD net sales growth is expected to be over 50% compared with 2025, full year share repurchases are expected to total approximately $3 billion, and 2027 R&D expense is expected to increase by a mid teens percentage compared with 2026, with 100 to 200 basis points of upward pressure on the 2027 effective tax rate relative to 2026. Regeneron does not anticipate recording any revenue in the fourth quarter of 2026 for Inmazeb and expects to supply additional treatment doses to the US government beginning in late 2027 through 2031; it also expects an FDA decision for cemdisiran in November, a European Commission decision in the second half of 27, pivotal results for the knee replacement factor 11 program starting next year, a potentially registrational POTS study in the first half of next year, and registrational studies of the olatorepatide and Praluent combination next year.
Regeneron Risk Analysis
Regeneron disclosed 47 risk factors in its most recent earnings report. Regeneron reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksRegeneron Peers Comparison
Overall Rating
ARGX76Outperform
ALNY71Outperform
GMAB71Outperform
INCY68.3Neutral
BMRN58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ARGX | 76Outperform | $56.77B | 41.24 | 16.86% | ― | 70.57% | 30.28% |
| ALNY | 71Outperform | $22.10B | 7.75 | 159.72% | ― | 56.17% | 6459.20% |
| GMAB | 71Outperform | $34.99B | 43.25 | 13.58% | ― | 21.75% | -36.69% |
| INCY | 68Neutral | $24.54B | 57.16 | 7.11% | ― | 24.88% | -65.67% |
| BMRN | 58Neutral | $11.33B | -638.22 | 1.18% | ― | 13.69% | -89.03% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IT:1REGN | Regeneron Pharmaceuticals | 863.80 | 313.62 | 57.00% | |
| ALNY | Alnylam Pharmaceuticals | 158.00 | -265.47 | -62.69% | |
| BMRN | Biomarin Pharmaceutical Inc. | 57.44 | 4.92 | 9.37% | |
| INCY | Incyte | 120.04 | 17.12 | 16.63% | |
| ARGX | Argenx | 874.97 | 43.49 | 5.23% | |
| GMAB | Genmab (Otc) | 54.92 | 26.16 | 90.96% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.